Yang, Zhicong
Chen, Qing
Dong, Shihua
Xu, Peng
Zheng, Wanxiang
Mao, Zhanrui
Qian, Chengchen
Zheng, Xiangyi
Dai, Lihe
Wang, Chengyang
Shi, Haoqing
Li, Jing
Yuan, Jianlin
Yu, Wenqiang
Xu, Chuanliang
Clinical trials referenced in this document:
Documents that mention this clinical trial
Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma
https://doi.org/10.1186/s12967-024-05420-3
Funding for this research was provided by:
National Key R&D Program of China (2018YFC1005004, 2022BEG01003)
Science and Technology Innovation Plan Of Shanghai Science and Technology Commission (16411969700, 17411950900)
National Natural Science Foundation of China (32270645, 32000505, 31671308, 31872814, 81572509, 81772720, 81802515, 82272950)
Article History
Received: 3 April 2024
Accepted: 19 June 2024
First Online: 2 July 2024
Declarations
:
: The study was approved by the ethic committee of the Shanghai Changhai Hospital (License Number: CHEC2022-033) and Fudan University Shanghai Cancer Center (License Number: 050432-4-1911D). This research conformed to the principles of the Helsinki Declaration. Written informed content was obtained from every participant.
: Not applicable.
: Shihua Dong used to be the R & D director of Epiprobe. Peng Xu used to be the employee of Epiprobe. Wenqiang Yu serves on the scientific advisory boards of Epiprobe. Shihua Dong has pending patents related to this work. All other authors declare no competing interests.